Trials / Completed
CompletedNCT02029430
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- ImmunityBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
Detailed description
This is an open-label pilot phase 2 study to investigate efficacy, safety, and intratumoral kinetics of aldoxorubicin in HIV-Infected patients with Kaposi's sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 50 mg/m2 aldoxorubicin | |
| DRUG | 100 mg/m2 aldoxorubicin | |
| DRUG | 150 mg/m2 aldoxorubicin |
Timeline
- Start date
- 2014-04-03
- Primary completion
- 2016-04-25
- Completion
- 2016-04-25
- First posted
- 2014-01-07
- Last updated
- 2024-06-11
- Results posted
- 2024-06-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02029430. Inclusion in this directory is not an endorsement.